Xencor to Participate at Upcoming Investor Conferences

Business Wire

27 Nov 2024

PASADENA, Calif., November 26, 2024--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT
Location: New York City

7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT
Location: Coral Gables, Florida

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126889211/en/

Contacts

Charles Liles
cliles@xencor.com
(626) 737-8118

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2486831073"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486831073\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486831073?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iFvtDx5RzynLBwOXfYIxzw--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/34b8913760c8a921d76b6837994ebe51","is_english":true,"pubTime":"2024-11-27 05:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486831073","market":"us","top_or_hot":-1,"title":"Xencor to Participate at Upcoming Investor Conferences","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"270\" src=\"https://s.yimg.com/uu/api/res/1.2/Gjrbun4MJazDAiXbbrBxvQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/34b8913760c8a921d76b6837994ebe51\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>PASADENA, Calif., November 26, 2024</b>--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:</p>\n<ul>\n<li><b>Piper Sandler 36th Annual Healthcare Conference </b><br/>Date: Tuesday, December 3, 2024<br/>Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT<br/>Location: New York City<br/><br/><br/><br/></li>\n</ul>\n<ul>\n<li><b>7th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference<br/></b>Date: Wednesday, December 4, 2024<br/>Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT<br/>Location: Coral Gables, Florida<br/><br/></li>\n</ul>\n<p>Live webcasts of the presentations will be available under \"Events &amp; Presentations\" in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.</p>\n<p><b>About Xencor</b></p>\n<p>Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241126889211/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Charles Liles<br/>cliles@xencor.com <br/>(626) 737-8118<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xencor to Participate at Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXencor to Participate at Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 05:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/xencor-participate-upcoming-investor-conferences-210100429.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PASADENA, Calif., November 26, 2024--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/xencor-participate-upcoming-investor-conferences-210100429.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/xencor-participate-upcoming-investor-conferences-210100429.html","article_id":"2486831073","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iFvtDx5RzynLBwOXfYIxzw--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/34b8913760c8a921d76b6837994ebe51"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486831073","pubTimestamp":1732654860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"PASADENA, Calif., November 26, 2024----Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:. Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024Presentation Time: 2:00 p.m. ET / 11:00 a.m. PTLocation: New York City. 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Presentation Time: 3:50 p.m. ET / 12:50 p.m. PTLocation: Coral Gables, Florida. Live webcasts of the presentations will be available under \"Events & Presentations\" in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and othe","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XNCR":"Xencor Inc"},"translate_title":"Xencor将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XNCR":1},"content_text":"PASADENA, Calif., November 26, 2024--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:\n\nPiper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024Presentation Time: 2:00 p.m. ET / 11:00 a.m. PTLocation: New York City\n\n\n7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Presentation Time: 3:50 p.m. ET / 12:50 p.m. PTLocation: Coral Gables, Florida\n\nLive webcasts of the presentations will be available under \"Events & Presentations\" in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.\nAbout Xencor\nXencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241126889211/en/\nContacts\nCharles Lilescliles@xencor.com (626) 737-8118","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}